1-7 of 7
M. Shah
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PO-032: Association of a polymorphic variant in JMJD1C with tumor recurrence after adjuvant chemoradiation therapy in head and neck squamous cell carcinoma

Adria Hasan, Elena V. Demidova, Shreya M. Shah, Philip Czyzewicz, Karthik Devarajan, Thomas Galloway, Barbara Burtness, Erica A. Golemis, Joshua E. Meyer, Sanjeevani Arora
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (18_Supplement): PO-032.
https://doi.org/10.1158/1557-3265.AACRAHNS23-PO-032
Published: 15 September 2023
View article titled, Abstract PO-032: Association of a polymorphic variant in <em>JMJD1C</em> with tumor recurrence after adjuvant chemoradiation therapy in head and neck squamous cell carcinoma
Journal Articles

The Role of the TP53 Pathway in Predicting Response to Neoadjuvant Therapy in Esophageal Adenocarcinoma

Smita Sihag, Samuel C. Nussenzweig, Henry S. Walch, Meier Hsu, Kay See Tan, Sergio De La Torre, Yelena Y. Janjigian, Steven B. Maron, Geoffrey Y. Ku, Laura H. Tang, Pari M. Shah, Abraham Wu, David R. Jones, David B. Solit, Nikolaus Schultz, Karuna Ganesh, Michael F. Berger, Daniela Molena
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (12): 2669–2678.
https://doi.org/10.1158/1078-0432.CCR-21-4016
Published: 13 June 2022
View article titled, The Role of the TP53 Pathway in Predicting Response to Neoadjuvant Therapy in Esophageal Adenocarcinoma
Open the PDF for The Role of the TP53 Pathway in Predicting Response to Neoadjuvant Therapy in Esophageal Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways

Smita Sihag, Samuel C. Nussenzweig, Henry S. Walch, Meier Hsu, Kay See Tan, Francisco Sanchez-Vega, Walid K. Chatila, Sergio A. De La Torre, Assem Patel, Yelena Y. Janjigian, Steven Maron, Geoffrey Y. Ku, Laura H. Tang, Jaclyn Hechtman, Pari M. Shah, Abraham J. Wu, David R. Jones, Daniela Molena, David B. Solit, Nikolaus Schultz, Michael F. Berger
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (12): 3491–3498.
https://doi.org/10.1158/1078-0432.CCR-20-4707
Published: 15 June 2021
View article titled, Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways
Open the PDF for Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways in another window
Includes: Supplementary data
Journal Articles

Abstract A58: An ovarian patient-derived xenograft model to identify the chemoresistant population

Zachary C. Dobbin, Ashwini K. Katre, Monjri M. Shah, Britt K. Erickson, Hauping Chen, Ronald D. Alvarez, Michael G. Conner, Dongquan Chen, Charles N. Landen
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (19_Supplement): A58.
https://doi.org/10.1158/1078-0432.OVCA13-A58
Published: 13 May 2014
View article titled, Abstract A58: An ovarian patient-derived xenograft model to identify the chemoresistant population
Journal Articles

Endoglin (CD105) Contributes to Platinum Resistance and Is A Target for Tumor-Specific Therapy in Epithelial Ovarian Cancer

Angela J. Ziebarth, Somaira Nowsheen, Adam D. Steg, Monjri M. Shah, Ashwini A. Katre, Zachary C. Dobbin, Hee-Dong Han, Gabriel Lopez-Berestein, Anil K. Sood, Michael Conner, Eddy S. Yang, Charles N. Landen
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (1): 170–182.
https://doi.org/10.1158/1078-0432.CCR-12-1045
Published: 02 January 2013
View article titled, Endoglin (CD105) Contributes to Platinum Resistance and Is A Target for Tumor-Specific Therapy in Epithelial Ovarian Cancer
Open the PDF for Endoglin (CD105) Contributes to Platinum Resistance and Is A Target for Tumor-Specific Therapy in Epithelial Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I Dose-Finding Study of Weekly Docetaxel Followed by Flavopiridol for Patients with Advanced Solid Tumors

M.N. Fornier, D. Rathkopf, M. Shah, S. Patil, E. O'Reilly, A.N. Tse, C. Hudis, R. Lefkowitz, D.P. Kelsen, G.K. Schwartz
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (19): 5841–5846.
https://doi.org/10.1158/1078-0432.CCR-07-1218
Published: 01 October 2007
View article titled, Phase I Dose-Finding Study of Weekly Docetaxel Followed by Flavopiridol for Patients with Advanced Solid Tumors
Open the PDF for Phase I Dose-Finding Study of Weekly Docetaxel Followed by Flavopiridol for Patients with Advanced Solid Tumors in another window
Journal Articles

6-Aminonicotinamide sensitizes human tumor cell lines to cisplatin.

I I Budihardjo, D L Walker, P A Svingen, C A Buckwalter, S Desnoyers, S Eckdahl, G M Shah, G G Poirier, J M Reid, M M Ames, S H Kaufmann
Journal: Clinical Cancer Research
Clin Cancer Res (1998) 4 (1): 117–130.
Published: 01 January 1998
View article titled, 6-Aminonicotinamide sensitizes human tumor cell lines to cisplatin.
Open the PDF for 6-Aminonicotinamide sensitizes human tumor cell lines to cisplatin. in another window